Valley National Advisers’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$286K Buy
4,719
+503
+12% +$29.3K 0.04% 216
2025
Q4
$227K Sell
4,216
-1,675
-28% -$80.6K 0.03% 229
2025
Q3
$265K Sell
5,891
-28,312
-83% -$1.32M 0.04% 206
2025
Q2
$1.58M Buy
34,203
+334
+1% +$16.4K 0.26% 100
2025
Q1
$2.06M Buy
33,869
+2,021
+6% +$118K 0.37% 64
2024
Q4
$1.8M Buy
31,848
+26,486
+494% +$1.48M 0.32% 79
2024
Q3
$277K Sell
5,362
-2,292
-30% -$108K 0.05% 208
2024
Q2
$317K Sell
7,654
-1,587
-17% -$71K 0.05% 202
2024
Q1
$501K Sell
9,241
-1,917
-17% -$97.7K 0.08% 164
2023
Q4
$572K Sell
11,158
-2,271
-17% -$119K 0.09% 147
2023
Q3
$779K Buy
13,429
+193
+1% +$11.8K 0.14% 121
2023
Q2
$847K Buy
13,236
+82
+0.6% +$5.5K 0.14% 122
2023
Q1
$928K Sell
13,154
-463
-3% -$32.7K 0.16% 111
2022
Q4
$979K Sell
13,617
-887
-6% -$66.9K 0.18% 106
2022
Q3
$1.04M Sell
14,504
-85
-0.6% -$6.17K 0.22% 95
2022
Q2
$1.1M Buy
14,589
+169
+1% +$12.9K 0.23% 86
2022
Q1
$1.05M Buy
14,420
+1,108
+8% +$74.4K 0.2% 106
2021
Q4
$830K Sell
13,312
-950
-7% -$55.7K 0.15% 130
2021
Q3
$844K Buy
14,262
+28
+0.2% +$1.84K 0.15% 124
2021
Q2
$951K Buy
14,234
+122
+0.9% +$7.96K 0.17% 117
2021
Q1
$891K Sell
14,112
-75
-0.5% -$4.67K 0.17% 117
2020
Q4
$880K Sell
14,187
-110
-0.8% -$6.76K 0.18% 111
2020
Q3
$862K Buy
14,297
+356
+3% +$21.4K 0.2% 84
2020
Q2
$820K Sell
13,941
-42
-0.3% -$2.51K 0.19% 82
2020
Q1
$779K Buy
13,983
+831
+6% +$50.8K 0.22% 83
2019
Q4
$844K Buy
13,152
+8,343
+173% +$478K 0.21% 87
2019
Q3
$244K Buy
4,809
+7
+0.1% +$329 0.07% 172
2019
Q2
$218K Buy
4,802
+7
+0.1% +$326 0.06% 169
2019
Q1
$229K Buy
4,795
+7
+0.1% +$349 0.07% 164
2018
Q4
$249K Buy
4,788
+37
+0.8% +$1.99K 0.08% 148
2018
Q3
$295K Buy
4,751
+180
+4% +$10.7K 0.1% 145
2018
Q2
$253K Sell
4,571
-3
-0.1% -$162 0.1% 154
2018
Q1
$289K Buy
4,574
+5
+0.1% +$322 0.11% 139
2017
Q4
$280K Sell
4,569
-596
-12% -$37.3K 0.1% 141
2017
Q3
$329K Buy
5,165
+40
+0.8% +$2.34K 0.11% 120
2017
Q2
$286K Buy
5,125
+5
+0.1% +$272 0.1% 117
2017
Q1
$278K Buy
5,120
+302
+6% +$16.6K 0.11% 120
2016
Q4
$282K Buy
4,818
+405
+9% +$22.1K 0.13% 118
2016
Q3
$238K Buy
4,413
+4
+0.1% +$257 0.12% 123
2016
Q2
$324K Buy
4,409
+4
+0.1% +$283 0.17% 117
2016
Q1
$281K Buy
4,405
+604
+16% +$38.1K 0.15% 118
2015
Q4
$261K Buy
3,801
+4
+0.1% +$264 0.15% 114
2015
Q3
$225K Buy
3,797
+4
+0.1% +$254 0.14% 121
2015
Q2
$252K Buy
3,793
+4
+0.1% +$264 0.14% 124
2015
Q1
$244K Buy
3,789
+828
+28% +$51.8K 0.14% 116
2014
Q4
$157K Buy
+2,961
New +$167K 0.12% 105

Other funds holding BMY

Valley National Advisers's BMY Position: Q1 2026 in Review

Valley National Advisers increased its Bristol-Myers Squibb (BMY) stake by 12% in Q1 2026, buying an estimated $29.3K and bringing the position to 4,719 shares worth $286K. The position accounts for 0.04% of the portfolio, ranked #216.

Valley National Advisers first reported a position in BMY in Q4 2014 and has held it in 46 quarters since. The position peaked at $2.06M in Q1 2025. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Valley National Advisers held 4,719 shares of Bristol-Myers Squibb worth $286K as of Q1 2026.
  • Valley National Advisers bought 503 Bristol-Myers Squibb shares in Q1 2026, an estimated $29.3K.
  • Bristol-Myers Squibb made up 0.04% of Valley National Advisers's portfolio in Q1 2026, its #216 holding.
  • Valley National Advisers first reported a position in Bristol-Myers Squibb in Q4 2014 and has held it in 46 quarters since.
  • Valley National Advisers's Bristol-Myers Squibb position peaked at $2.06M in Q1 2025.
  • 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Valley National Advisers's 13F filing for Q1 2026, filed 15 Apr 2026.